Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
Top Page
Y-Mabs Therapeutics
(NASDAQ:YMAB)
Rating:44Neutral
Price Target:―
Positive Factors
Clinical Trials Progress
Management disclosed results from Part A of the ongoing Phase 1/2 trial, demonstrating tumor uptake of 177 in all nine patients with positive GD2 expression.
Therapy Enhancement
The improved compound will be incorporated into a Bridge study, indicating ongoing efforts to enhance the therapy.
Negative Factors
Investor Confidence
The timeline for bridging study and additional dose escalation pushes key derisking back, impacting investor confidence.
Therapeutic Index Challenges
The results for GD2-SADA show that further optimization is required, as no cohort demonstrated an optimal therapeutic index.
Y-Mabs Therapeutics (YMAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$238.64M
Dividend YieldN/A
Average Volume (3M)198.32K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue Growth3.38%
EPS Growth-36.40%
CountryUS
Employees104
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.12
Shares Outstanding45,283,676
10 Day Avg. Volume176,388
30 Day Avg. Volume198,319
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-11.21
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit1.51
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$13.86Price Target Upside172.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Y-Mabs Therapeutics Business Overview & Revenue Model
Company DescriptionY-Mabs Therapeutics, Inc. (YMAB) is a biopharmaceutical company focused on the development and commercialization of innovative antibody-based products for the treatment of cancer. The company specializes in developing therapies for pediatric oncology and orphan diseases, using its proprietary radioimmunotherapy platform aimed at targeting tumors with precision. Its lead product candidates target neuroblastoma, a rare cancer affecting children, as well as other solid tumor indications.
How the Company Makes MoneyY-Mabs Therapeutics generates revenue primarily through the development and commercialization of its proprietary therapeutic products. The company earns money by bringing its drug candidates to market, which involves obtaining regulatory approvals, manufacturing the drugs, and distributing them through various healthcare channels. In addition to direct sales of their approved products, Y-Mabs may enter into strategic partnerships or licensing agreements with other pharmaceutical companies to co-develop or market its products, which can provide upfront payments, milestone payments, and royalties. Furthermore, the company may receive government grants or incentives for developing treatments for rare diseases, which can contribute to its revenue stream.
Y-Mabs Therapeutics Earnings Call Summary
Earnings Call Date:May 13, 2025
(Q1-2025)
| % Change Since: 24.82%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call presented several positive developments such as revenue growth in DANYELZA, especially internationally, and advancements in the Radiopharmaceutical segment. However, there were notable challenges like the significant decline in U.S. revenues and reduced R&D expenses. The sentiment is mixed with balanced highlights and lowlights.Q1-2025 Updates
Positive Updates
DANYELZA Revenue Growth
DANYELZA net product revenues reached $20.9 million in Q1 2025, an 8% increase from the first quarter of 2024, driven by strong growth outside the U.S.
Strong Financial Position
The company maintains a strong financial position with $60.3 million in cash, providing an anticipated runway into 2027.
Ex-U.S. Revenue Surge
Ex-U.S. DANYELZA net product revenues were $7.5 million, an 816% increase compared to the prior year period, driven by growth in Western Asia, Eastern Asia, and Latin America.
Radiopharmaceutical R&D Progress
The first patient was dosed in the CD38-SADA Phase I clinical trial, and Part A of the GD2-SADA Phase I clinical trial was completed, marking significant progress in the Radiopharmaceutical business unit.
NCCN Guidelines Inclusion
DANYELZA, in combination with chemotherapy, was added to NCCN guidelines for the treatment of relapsed or refractory neuroblastoma, potentially enhancing its market position.
Negative Updates
U.S. Revenue Decline
U.S. net product revenues for DANYELZA decreased by 28% compared to the prior year period, due to competitive pressures and changes in ordering patterns.
Research and Development Expense Reduction
Research and development expenses decreased by $1.9 million due to timing of completion of clinical trials, which may indicate a slowdown in R&D activities.
Guidance Indicates Potential Revenue Decline
Q2 2025 total revenue guidance of $17-19 million suggests a potential revenue decline compared to Q1 2025.
Company Guidance
During the Y-mAbs Therapeutics First Quarter 2025 Earnings Conference Call, several key metrics and guidance for the company were highlighted. The company reported DANYELZA net product revenues of $20.9 million for the first quarter of 2025, marking an 8% increase from the previous year. This growth was driven primarily by Ex-U.S. revenues, which saw an 816% increase to $7.5 million, largely due to the named patient program in Western Asia. Despite a challenging U.S. market, the company maintained a strong financial position with $60.3 million in cash, anticipating a runway into 2027. Research and development expenses decreased to $11.4 million, while selling, general, and administrative expenses increased to $13.1 million. The company also reported a net loss of $5.2 million, a decrease from the previous year's $6.6 million. Looking forward, Y-mAbs reiterated its full-year 2025 guidance and announced second-quarter revenue expectations of $17 million to $19 million, aligning with seasonal trends. The company also plans to update its Radiopharmaceutical pipeline and GD2-SADA Phase I trial data on May 28.Y-Mabs Therapeutics Financial Statement Overview
Summary
Y-Mabs Therapeutics shows revenue growth and a strong equity position but struggles with profitability and cash flow sustainability. The biotech industry demands significant R&D investments, reflected in the financials. Although the balance sheet indicates stability, addressing operational losses is crucial for financial improvement.Income Statement
Y-Mabs Therapeutics has shown revenue growth over recent years, with total revenue increasing from $20.75 million in 2020 to $87.68 million in 2024. However, the company is still facing significant challenges with profitability. The EBIT and EBITDA margins remain negative, indicating ongoing operational losses. The net profit margin is also negative, highlighting the unprofitable nature of the business at present.45
Neutral
Balance Sheet
The company maintains a strong equity position with a low debt-to-equity ratio of 0.009 in 2024, suggesting limited financial leverage risk. However, the return on equity remains negative due to net losses, and the equity ratio is robust, reflecting financial stability. The liquidity position, with substantial cash reserves, supports operational needs despite losses.60
Neutral
Cash Flow
Operating cash flow remains negative, indicating cash consumption from operations. Free cash flow has improved slightly but is still negative, showing reliance on financing activities. The operating cash flow to net income ratio suggests continued cash burn, posing challenges to sustainability without external funding.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 87.69M | 84.82M | 65.27M | 34.90M | 20.75M | Gross Profit |
| 72.43M | 73.40M | 57.70M | 32.38M | 18.55M | EBIT |
| -31.20M | -25.67M | -94.81M | -115.43M | -119.94M | EBITDA |
| -30.67M | -24.94M | -94.73M | -54.49M | -119.54M | Net Income Common Stockholders |
| -29.67M | -21.43M | -96.33M | -56.34M | -118.34M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 67.23M | 78.64M | 105.76M | 181.56M | 114.63M | Total Assets |
| 119.90M | 127.87M | 141.46M | 212.78M | 132.05M | Total Debt |
| 820.00K | 1.42M | 1.77M | 3.63M | 3.98M | Net Debt |
| -66.41M | -77.22M | -104.00M | -177.93M | -110.66M | Total Liabilities |
| 27.90M | 26.88M | 32.23M | 32.68M | 26.21M | Stockholders Equity |
| 92.00M | 100.98M | 109.22M | 180.11M | 105.84M |
| Cash Flow | Free Cash Flow | |||
| -15.71M | -27.23M | -75.92M | -103.52M | -91.41M | Operating Cash Flow |
| -15.71M | -27.23M | -75.92M | -102.56M | -91.23M | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | 61.04M | -2.79M | Financing Cash Flow |
| 4.31M | 100.00K | 84.00K | 108.31M | 2.00M |
Y-Mabs Therapeutics Technical Analysis
Positive
5.08
Price Trends
4.42
Positive
5.01
Positive
8.62
Negative
Market Momentum
0.22
Negative
62.23
Neutral
82.75
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YMAB, the sentiment is Positive. The current price of 5.08 is above the 20-day moving average (MA) of 4.46, above the 50-day MA of 4.42, and below the 200-day MA of 8.62, indicating a neutral trend. The MACD of 0.22 indicates Negative momentum. The RSI at 62.23 is Neutral, neither overbought nor oversold. The STOCH value of 82.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for YMAB.
Y-Mabs Therapeutics Risk Analysis
Y-Mabs Therapeutics disclosed 76 risk factors in its most recent earnings report. Y-Mabs Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Y-Mabs Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $370.49M | ― | -86.53% | ― | -7.84% | 42.34% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
48 Neutral | $258.12M | ― | -74.15% | ― | -3.61% | -3.39% | |
47 Neutral | $162.78M | ― | -20.42% | ― | -18.80% | 26.16% | |
44 Neutral | $238.64M | ― | -29.93% | ― | 3.38% | -36.40% | |
34 Underperform | $311.34M | ― | -34.97% | ― | ― | -140.77% |
* Healthcare Sector Average
Performance Comparison
YMAB
Y-Mabs Therapeutics
5.08
-6.93
-57.70%
ANIK
Anika Therapeutics
11.52
-14.34
-55.45%
CRDF
Cardiff Oncology
3.86
0.91
30.85%
NGNE
Neurogene
19.91
-17.27
-46.45%
OM
Outset Medical
21.24
-42.81
-66.84%
Y-Mabs Therapeutics Corporate Events
Business Operations and Strategy
Y-mAbs Therapeutics Updates on Business and Clinical Trials
Neutral
Jan 13, 2025
Y-mAbs Therapeutics, Inc. has released a corporate overview presentation on its investor relations website, which includes updates on its business operations, clinical trials, and development pipeline. This presentation is intended for investor meetings and a podium presentation at the J.P. Morgan Healthcare Conference, indicating the company’s ongoing engagement with investors and stakeholders in the biopharmaceutical industry.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.